OMA Guidelines Bundle

Obesity Pharmacotherapy Supplements 2026

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1544296

Contents of this Issue

Navigation

Page 7 of 19

8 Medication and Supplement History Currently Available OTC Medications, Supplements, and Vitamins Marketed for Weight Reduction OTC Medications • Orlistat (Alli 60 mg): lower-dose version of prescription Orlistat Dietary Supplements Multiple compounds are available with limited FDA review or regulation. These products may have various formulations and often lack standardization. These products may be labeled as "fat burners," "metabolism boosters," or "appetite suppressants," with limited data. Some common examples and the proposed mechanisms of action include: • Herbal products (multiple proposed mechanisms): Green tea extract, Garcinia cambogia, white kidney bean extract. • Fiber supplements (promote satiety and may reduce intake): Glucomannan, psyllium, cellulose. • Stimulants (reduce appetite via sympathetic activation): Caffeine, bitter orange. • Other compounds: Conjugated linoleic acid, L-carnitine, raspberry ketones, capsaicin, chitosan, B vitamins (individual and complexes). • Elemental compounds: Chromium, calcium, magnesium. Previously Available Supplements and OTC Compounds That Have Been Removed from the Market • Thyroid hormone: Used in the 1890s; risk of cardiac arrhythmias and sudden death. • Ephedra: Banned in 2004 due to cardiovascular adverse effects. • Phenylpropanolamine: Banned in 2000 due to increased risk of hemorrhagic stroke. • 2,4-Dinitrophenol: Previously used in some weight loss supplements, now illegal for human consumption due to severe adverse effects, including hyperthermia and death.

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy Supplements 2026